News brief­ing: Small merg­er to ad­vance an­ti-ag­ing pro­gram; Sanger In­sti­tute spin­out nabs $50M from Se­ries C

5 years ago
News Briefing

French health prod­ucts agency yanked in­to le­gal bat­tle over birth de­fects caused by Sanofi's De­pakine

5 years ago
Pharma
FDA+

Pfiz­er’s cel­e­brat­ed Covid-19 vac­cine freezes many peo­ple out — but a ri­val mR­NA team says they thawed out a ...

5 years ago
R&D

Jim Wil­son of­fers a safer so­lu­tion to some of the in­dus­try's gene ther­a­py woes

5 years ago
R&D
Cell/Gene Tx

Chas­ing a 'mas­ter mod­u­la­tor' in the en­do­cannabi­noid sys­tem, biotech up­start promis­es to shake up neu­ropsy­chi­atric ...

5 years ago
Financing
Startups

UCB is beef­ing up its gene ther­a­py ops with back-to-back deals to buy a start­up and sign up a uni­ver­si­ty spin­out for ...

5 years ago
Deals
Cell/Gene Tx

Un­der a new CEO, Ger­man CD­MO Viba­log­ics bets $150M and 110,000 square feet on the gene ther­a­py rev­o­lu­tion

5 years ago
Outsourcing
Cell/Gene Tx

Ki­ra Phar­ma­ceu­ti­cals emerges from stealth with $46M and new CEO to lead com­ple­ment ther­a­py mis­sion

5 years ago
Financing
Startups

Bay­er fronts $65M Se­ries A for Metageno­mi, a gene ther­a­py biotech aim­ing to find new CRISPR en­zymes

5 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: Po­lit­i­cal pres­sures at FDA con­tin­ue post-elec­tion; Med­ica­go takes GSK ad­ju­vant in­to its first ...

5 years ago
Coronavirus

Mod­er­na says it's reached the re­quired num­ber of Covid-19 cas­es for its first in­ter­im analy­sis. When is the read­out ...

5 years ago
Coronavirus

Gates Foun­da­tion backs a new sick­le cell CRISPR ap­proach; Sid­dhartha Mukher­jee's Vor adds a new CAR-T

5 years ago
News Briefing

Sil­ver­back files to go pub­lic, po­ten­tial­ly adding to this year's record-high biotech IPO raise

5 years ago
Financing

Pfiz­er, still chas­ing Dupix­ent, re­leas­es fifth round of da­ta for eczema JAK in­hibitor abroc­i­tinib

5 years ago
R&D

Top an­a­lyst sizes up wind­fall bil­lions for Pfiz­er, Re­gen­eron and Eli Lil­ly in a big week for the Covid-19 R&D race

5 years ago
R&D

A can­cer vac­cine that might work? Mod­er­na posts 'promis­ing' ear­ly snap­shot for Mer­ck-part­nered pro­gram and raids ...

5 years ago
R&D

Gov­ern­ment gears for un­prece­dent­ed chal­lenge of Eli Lil­ly an­ti­body roll­out as ef­fi­ca­cy ques­tions linger

5 years ago
Pharma
Coronavirus

Small biotech Inipharm lands $35M to take new NASH ap­proach, di­verg­ing from RNAi com­peti­tors

5 years ago
Financing

Ex­pect­ed mis­takes, the need for speed, and change to come: CBER's Pe­ter Marks looks ahead

5 years ago
FDA+

Five Prime claims a big win in topline da­ta for their come­back gas­tric can­cer drug as shares sky­rock­et

5 years ago
R&D

As Pfiz­er's stock surged Mon­day, Al­bert Bourla net­ted $5.6M in stock sales

5 years ago
People
Coronavirus

Cit­ing tox­i­c­i­ty con­cerns, Boehringer In­gel­heim drops short-lived IPF pact — keep­ing $1B+ in its pock­et

5 years ago
Deals

Covid-19 roundup: Sinopharm touts 'bet­ter than ex­pect­ed' PhI­II vac­cine da­ta; Af­ter Pfiz­er/BioN­Tech, Rus­sia claims ...

5 years ago
Coronavirus

A few months af­ter emerg­ing from stealth, Prax­is is hand­ed a clin­i­cal hold for lead de­pres­sion drug

5 years ago
R&D
FDA+
First page Previous page 778779780781782783784 Next page Last page
A service from the Financial Times